tbuckley/cabot-search huggingface dataset:
1192P Smoking adversely affects survival of metastatic lung carcinoid patients: Analysis of a large international audit
Authors: S. Valpione, A. Clarke, A. Cunningham, A. Garcia Alvarez, L. Spurgeon, R.D. Morgan, A. Carmona, J. Hernando, J. Capdevila Castillon, A. Backen, L. Campana, P. Manoharan, A. Verma, G. Lord, W. Mansoor
Journal: Annals of Oncology (2023)
1919MO Efficacy and safety of botensilimab (BOT) plus balstilimab (BAL) in patients (pts) with refractory metastatic sarcoma
Authors: B. Wilky, J.C. Trent, M. Gordon, A.B. El-Khoueiry, A. Bullock, B.S. Henick, G.K. Schwartz, M. Agulnik, D. Mahadevan, J. Patel, J. Grossman, K. Rosenthal, S.J. O'Day, A.M. Tsimberidou
Journal: Annals of Oncology (2023)
2402P Urine-based comprehensive genomic profiling reveals mutational landscape in real-world patients with bladder cancer
Authors: H. Chen, R. Zhang, H. Tang, J. Zang, D. Jin, L. Qian, T. Zhang, F. Xie, X. Zhang, Y. Zhang, S. Jia, G. Zhuang
Journal: Annals of Oncology (2023)
1926P Trabectedin plus radiotherapy on symptomatic advanced sarcoma patients: Results from the SYNERGIAS study - A Spanish group for research in sarcoma (GEIS) phase II study
Authors: J. Martin-Broto, K. Kopeckova, I. Azinovic, J. Cruz Jurado, L. Guzmán, R.M. Alvarez, A. Casado Herraez, C.M. Valverde Morales, A. Redondo Sanchez, R. Teres Lleida, A. Alvarez Gonzalez, M.C. Dolado, A. Doval, B. Belinchón, J.A. Merino, R. Mendez, P. Ledesma, A. Gutierrez, D. Da Silva Moura, N. Hindi Muñiz
Journal: Annals of Oncology (2023)
2386P Factors associated with not receiving systemic treatment (tx) in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a retrospective observational study in Germany
Authors: G. Niegisch, M. Kearney, J. Krieger, U. Osowski, C. Weinhold, B. Deiters, U. Maywald, S. Guenther, T. Wilke, M-O. Grimm
Journal: Annals of Oncology (2023)
2379P AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM)
Authors: P. Barthelemy, Y. Loriot, A. Flechon, M. Gross Goupil, E. Voog, J-C. Eymard, V. Lorgis, D. Pouessel, L. Francois, C. Sajous, D. Chocteau Bouju, A. Guillot, J. Long, E. Amela, C. Josse, M-N. Solbes, P. Lambert, C. Thibault
Journal: Annals of Oncology (2023)
1910P Evaluation of a genome-wide methylome enrichment platform for circulating tumor DNA quantification and prognostic performance in renal cell carcinoma (RCC)
Authors: B.I. Rini, J. Zhang, O. Hall, J. Bergener, Y. Wang, B. Brown, J. Min, S.Y. Shen, N. Fleshner, A. Polio, E. Sosa, S. Bratman, B. Allen, K. Brown, A. Licon, A-R. Hartman, D.D. De Carvalho, B. Ho Park, G. Liu
Journal: Annals of Oncology (2023)
2380P Real-world effectiveness of single agent enfortumab vedotin (EV) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) based on line of therapy and impact of prior platinum (plat) chemotherapy (chemo) and PD-1/PD-L1 inhibitors (PD-1/PD-L1i)
Authors: N. Sayegh, Y. Jung Jo, G. Gebrael, N. Tripathi, B. Chigarira, A. Srivastava, B. Nordblad, E. Dal, C. Hage Chehade, B.L. Maughan, S. Gupta, N. Agarwal, U. Swami
Journal: Annals of Oncology (2023)
1971P Metastatic osteosarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Authors: M. Reich, D. Dinart, H. Bellio, J. Berchoud, M. Jean-Denis, M. Bonneau, S. Winter, M. Larroquette, R. Duong, S. Nannini, J. Gantzer, B. Narciso, S. Piperno-Neumann, T. Valentin, M. Brahmi, E. Bompas, A. Le Cesne, P. Boudou Rouquette, C. Bellera, M. Toulmonde
Journal: Annals of Oncology (2023)
1920MO Regomune: A phase II study of regorafenib + avelumab in solid tumors - Results of the advanced or metastatic gastrointestinal stromal tumors (mGIST) cohort
Authors: S. Cousin, C. Bellera, J-P. Guegan, T. Valentin, B. Verret, J-P. Metges, A. Adenis, P. Cassier, F. Bouteiller, M. Spalato Ceruso, I. Korakis, A. Hollebecque, P.G. Poureau, J. Palussiere, M. Kind, I. Soubeyran, A. Bessede, A. Italiano
Journal: Annals of Oncology (2023)
2201P Malignant pleural mesothelioma (MPM)-specific DNA methylation patterns in patients using liquid biopsies
Authors: S. Schmid, S. Ul Haq, L.J. Zhan, M.C. Brown, D. Patel, F.A. Shepherd, N. Leighl, A. Sacher, M. de Perrot, J. Cho, F. Zaeimi, B. Lok, S. Bratman, M-S. Tsao, M. Frueh, P. Bradbury, G. Liu
Journal: Annals of Oncology (2023)
1936P Targeted therapy of desmoplastic small round cell tumor guided by multilayered molecular profiling
Authors: M. Renner, M. Oleś, N. Paramasivam, A. Schneider, C.E. Heilig, C. Modugno, C. Herremans, A. Mock, D. Lipka, S. Bauer, T. Kindler, C.H. Brandts, U. Keilholz, M. Boerries, B. Kuster, D. Hübschmann, M. Schlesner, H. Glimm, R.F. Schlenk, S. Fröhling
Journal: Annals of Oncology (2023)
Lipid nanovehicles overcome barriers to systemic RNA delivery: Lipid components, fabrication methods, and rational design
Authors: Jing Yan, Hao Zhang, Guangfeng Li, Jiacan Su, Yan Wei, Can Xu
Journal: Acta Pharmaceutica Sinica B (2023)

Lipid nanovehicles are currently the most advanced vehicles used for RNA delivery, as demonstrated by the approval of patisiran for amyloidosis therapy in 2018. To illuminate the unique superiority of lipid nanovehicles in RNA delivery, in this review, we first introduce various RNA therapeutics, describe systemic delivery barriers, and explain the lipid components and methods used for lipid nanovehicle preparation. Then, we emphasize crucial advances in lipid nanovehicle design for overcoming barriers to systemic RNA delivery. Finally, the current status and challenges of lipid nanovehicle-based RNA therapeutics in clinical applications are also discussed. Our objective is to provide a comprehensive overview showing how to utilize lipid nanovehicles to overcome multiple barriers to systemic RNA delivery, inspiring the development of more high-performance RNA lipid nanovesicles in the future.
2166P Long-term consequences of SARS-CoV-2 infection in cancer patients
Authors: Y. Debie, Z. Palte, H. Salman, L. Verbruggen, G. Vanhoutte, S. Raats, E. Roelant, T. Vandamme, M. Peeters, P.A. van Dam
Journal: Annals of Oncology (2023)
1939P phase I clinical results of SQ3370, a doxorubicin-based click chemistry therapeutic in advanced solid tumor patients
Authors: S.P. Chawla, V. Kwatra, V. Subbiah, N. Bui, V.A. Bhadri, M.C. Weiss, M. Agulnik, C.W. Ryan, M. Aleckovic, S. Srinivasan, M. Zakharian, T-H. Nguyen, J. Mejía Oneto, S. Abella, A.D. Guminski
Journal: Annals of Oncology (2023)
1938P Assessment of clinical benefit of cancer drugs recommended in National Comprehensive Cancer Network (NCCN) guidelines for advanced soft tissue sarcomas (STS) and bone sarcomas (BS)
Authors: M. Aguado Sorolla, R. Teres Lleida, A. Piedra, A.R. Cardozo, F. Bosma, P. Cerda Serda, A. Lopez Pousa, A. Tibau, A. Sebio Garcia
Journal: Annals of Oncology (2023)
1980P Artificial intelligence analysis shows enhanced CCNG1 expression in sarcoma tumors, a novel biomarker for DeltaRex-G tumor targeted retrovector encoding a CCNG1 inhibitor gene
Authors: S.P. Chawla, N. Omelchenko, C. Eid, S. Jeffrey, Z. Shekhovtsova, K. Suryamohan, E. Younesi, A. Omelchenko, A. Ahari, C. Valencia, N.S. Chawla, D. Brigham, E.M. Gordon
Journal: Annals of Oncology (2023)
1925P Results of SOC-2082 phase II study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab as second/third-line therapy for advanced leiomyosarcoma
Authors: N.S. Chawla, N. Omelchenko, S. Makrievski, G. Leão De Melo, D. Brigham, A. Ahari, V.S. Chua Alcala, A. Moradhkani, D. Quon, S. Wong, S.P. Chawla, E.M. Gordon
Journal: Annals of Oncology (2023)
2394P Biomarkers of treatment (Tx)-related toxicity in advanced urothelial carcinoma (aUC) pts treated with enfortumab vedotin (EV): Analysis of UNITE study
Authors: A. Nizam, L. Zhang, T. Jindal, C.B. Nguyen, O. Alhalabi, A. Basu, S.P. Evans, C.J. Hoimes, Y. Zakharia, M.I. Milowsky, D. Kilari, S.A. Shah, N.B. Davis, H. Emamekhoo, S. Gupta, J. Bellmunt, P. Grivas, M.T. Campbell, A. Alva, V.S. Koshkin
Journal: Annals of Oncology (2023)
2385P Long-term survival upon anti-PD-(L)1 monotherapy in metastatic urothelial cancer (mUC): A multicenter retrospective study
Authors: C.F. Stockem, S. Einerhand, I. Miras Rodriguez, B. Perez Valderrama, C. Vulsteke, A.M. De Meulenaere, R. Morales Barrera, J. Carles Galceran, P. Giannatempo, A. Rametta, A. Bottelli, F. Lefort, D.R. Bakaloudi, R. Talukder, P. Grivas, M.S. van der Heijden
Journal: Annals of Oncology (2023)
1957P Results from a phase I/II trial of tinostamustine monotherapy in advanced solid tumours (NCT03345485): Safety and efficacy in a subset of patients (pts) with soft tissue sarcoma (STS)
Authors: R. Chugh, S. Kummar, R.E. Schneider, T. Janik, N. Manamley, K. Hilgier, J. Strauss
Journal: Annals of Oncology (2023)
2197P Prognostic value of 18F-FDG-PET for patients with malignant pleural mesothelioma treated with double immunotherapy
Authors: S.M.H. Thunold, E. Hernes, S.J. Farooqi, L.T.G. Mikalsen, A.K. Ojlert, A. Helland, E. Malinen, V.D. Haakensen
Journal: Annals of Oncology (2023)
2203P Uncovering prognostic transcriptomic differences in epithelioid malignant pleural mesothelioma
Authors: M. Occhipinti, M. Brambilla, P. Ambrosini, A. Pannone, C. Zanella, A.G. Leone, R. Leporati, G. Fotia, R. Di Mauro, A. Ianza, S. Manglaviti, T. Beninato, L. Mazzeo, C. Proto, A. Prelaj, S. Percio, F.G.M. De Braud, G. Lo Russo, D. Generali, M. Ganzinelli
Journal: Annals of Oncology (2023)
1915MO Fear, anxiety and depression in gastrointestinal stromal tumor (GIST) patients in the Netherlands: Data from a cross-sectional multicenter study
Authors: D. van de Wal, D. Den Hollander, I.M. Desar, H. Gelderblom, A.W. Oosten, A.K.L. Reyners, N. Steeghs, W.T.A. Van Der Graaf, O. Husson
Journal: Annals of Oncology (2023)
1914MO The clinico-radiological outcome of desmoid type-fibromatosis after discontinuing the sorafenib treatment in responders: Single-arm phase II clinical trial
Authors: B. Bharath, S. Rastogi, V. Garg, G. Tansir, E. Dhamija, A. Barwad, S. Kaur, S. Gamanagatti, S. Bhoriwal, M. Khan
Journal: Annals of Oncology (2023)
2392P Tislelizumab combined with gemcitabine/cisplatin in muscle-invasive bladder cancer with selective bladder preservation for clinical complete response (cCR) patients: A real-world multicenter study
Authors: B. Huang, Z. Wang, B. Wang, D. Yuan, H. Lin, A. Xu, P. Liu, J. Chen
Journal: Annals of Oncology (2023)
2391P Impact of perioperative chemotherapy on survival and pathological stage in muscle-invasive micropapillary urothelial bladder cancer
Authors: A.M. Roy, A. Groman, V. Muthusamy Kumarasamy, A. Patel, K. Jatwani, K. Attwood, K. Guru, G. Chatta, D. Gopalakrishnan
Journal: Annals of Oncology (2023)
1976P Financial difficulties experienced by gastrointestinal stromal tumor (GIST) patients in the Netherlands: Data from a cross-sectional multicenter study
Authors: D. van de Wal, D. Den Hollander, I.M. Desar, H. Gelderblom, A.W. Oosten, A.K.L. Reyners, N. Steeghs, W.T.A. Van Der Graaf, O. Husson
Journal: Annals of Oncology (2023)
1913O A randomised, multicenter phase-III study comparing doxorubicin (dox) alone versus dox with trabectedin (trab) followed by trab in non-progressive patients (pts) as first-line therapy, in pts with metastatic or unresectable leiomyosarcoma (LMS): Final results of the LMS-04 study
Authors: P. Pautier, A. Italiano, S. Piperno-Neumann, C.M. Chevreau, N. Penel, N. Firmin, P. Boudou Rouquette, F. Bertucci, V. Le Brun-Ly, I.L. Ray-Coquard, E. Kalbacher, E. Bompas, O. Collard, N. Isambert, C. Guillemet, M. Rios, A. Le Cesne, B. Archambaud, F. Duffaud
Journal: Annals of Oncology (2023)
1942P Non-metastatic malignant phyllodes tumors of the breast (B-MPT): A retrospective analysis from a referral center
Authors: C. Valenza, T.M. De Pas, G. Castellano, C. Santoro, A. Corona, G. Chiappini, G. Vivanet, D. Trapani, F. Conforti, S. Coppola, D. Mattar, P. Veronesi, E. Pennacchioli, G. Curigliano
Journal: Annals of Oncology (2023)
Leveraging immunoliposomes as nanocarriers against SARS-CoV-2 and its emerging variants
Authors: Nur Dini Fatini Mohammad Faizal, Nurul Afina Ramli, Nur Najihah Izzati Mat Rani, Nur Adania Shaibie, None Aarti, Pattaporn Poonsawas, Sunil K. Sharma, Mohd Cairul Iqbal Mohd Amin
Journal: Asian Journal of Pharmaceutical Sciences (2023)

The global COVID-19 pandemic arising from SARS-CoV-2 has impacted many lives, gaining interest worldwide ever since it was first identified in December 2019. Till 2023, 752 million cumulative cases and 6.8 million deaths were documented globally. COVID-19 has been rapidly evolving, affecting virus transmissibility and properties and contributing to increased disease severity. The Omicron is the most circulating variant of concern. Although success in its treatment has indicated progress in tackling the virus, limitations in delivering the current antiviral agents in battling emerging variants remain remarkable. With the latest advancements in nanotechnology for controlling infectious diseases, liposomes have the potential to counteract SARS-CoV-2 because of their ability to employ different targeting strategies, incorporating monoclonal antibodies for the active and passive targeting of infected patients. This review will present a concise summary of the possible strategies for utilizing immunoliposomes to improve current treatment against the occurrence of SARS-CoV-2 and its variants.
1984P Sex differences in anticancer treatment delivery and toxicity in patients with sarcoma in a reference center
Authors: I. Tortorelli, B. Chiusole, F. Murtas, A. Galiano, M. Bolshinsky, S. Ahcene Djaballah, C. De Toni, S. Vizzaccaro, M. Maruzzo, U. Basso, A. Banzato, M. Coppola, V. Zagonel, A. Brunello
Journal: Annals of Oncology (2023)
1904P Treatment options and outcome of metastatic renal cell carcinoma patients with brain or bone metastases: A real-world evidence from a German retrospective multi-center analysis
Authors: P. Paffenholz, P. Ivanyi, J. Wiegmann, J. Casuscelli, R. Wullenkord, S. Zschäbitz, C. Darr, T. Hilser, M. Schostak, M. Gür, K. Schlack, A. Handke, S. Hijazi, A. Heidenreich, V. Grünwald
Journal: Annals of Oncology (2023)
1909P Baseline cytokine levels according to the line of treatment in patients with metastatic clear cell renal cell carcinoma treated with nivolumab: NIVOREN GETUG-AFU 26 translational study
Authors: L.T. Rainho, L. Albiges, R. Flippot, L. Carril Ajuria, C. Dalban, B. Escudier, M. Naigeon, A. Desnoyer, M. Teixeira, N. Chaput-Gras
Journal: Annals of Oncology (2023)
1930P phase II trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (KCSG UN18-06)
Authors: Y.S. Kim, M. Kim, J-H. Ahn, J.E. Kim, Y.J. Kim, J.Y. Hong, S.J. Lee, S.Y. Oh, J.H. Kim, M.S. Ahn, W. Choi, E.Y. Kim, J-H. Jeong, W-S. Lee, K.B. Lee, T. Lee, C. Oum
Journal: Annals of Oncology (2023)
1917MO CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor
Authors: Y. Naito, Y. Komatsu, Y. Kurokawa, H. Hirano, T. Nishida, T. Doi
Journal: Annals of Oncology (2023)
1982P Transcriptomic analysis and tumor microenvironment (TME) classification reveals unique immune biology in HIV patients with Kaposi sarcoma (KS)
Authors: J. Yang, A. Sevkoplyas, S. Podsvirova, A. Tyshevich, M. Wang, M. Lee, H. Narvel, K. Zornikova, N. Shin, N. Kotlov, E. Postovalova, L. Paoluzzi, C. Zhu, B. Halmos, X. Zang, H. Cheng
Journal: Annals of Oncology (2023)
1974P Improved risk stratification with a prognostic nomogram incorporating the KIT-Variant Allele Frequency (VAF) and the 557/558 deletions: Results from a multi-institutional study in a cohort of intermediate-risk GIST patients
Authors: L. Incorvaia, D. de Biase, A. Gottardo, M. Nannini, C. Brando, E.R. Fumagalli, B. Vincenzi, I. De Luca, A. Dimino, M.A. Pantaleo, S. Gasperoni, L. D'Ambrosio, G. Grignani, L. Algeri, T.D. Bazan Russo, V. Gristina, A. Galvano, V. Bazan, A. Russo, G. Badalamenti
Journal: Annals of Oncology (2023)
1922P Immunosarc II master trial: phase II of sunitinib and nivolumab in vascular sarcomas cohort - A GEIS, ISG and UCL study
Authors: N. Hindi Muñiz, J. Martinez Trufero, G. Grignani, A. Sebio Garcia, S. Strauss, S. Stacchiotti, E. Gonzalez Billalabeitia, I.C. Carrasco Garcia, R. Ramos, A. Gutierrez, D. Da Silva Moura, M. Renshaw, P. Ledesma, J. Martin-Broto
Journal: Annals of Oncology (2023)
1883MO MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC)
Authors: M.H. Voss, B. Garmezy, S.H. Kim, J.P. Maroto Rey, A.B. Mansinho, A. Rodriguez-Vida, J. Oliveira, M. van Dongen, L. Medina Rodríguez, S. Negrier, B. Tran, B.A. Carneiro, E. Castanon Alvarez, S.Y. Rha, Y. Wang, S.D. Gainer, Z. Tang, I. Achour, J.M. Asare, L. Albiges
Journal: Annals of Oncology (2023)
1987TiP Pembrolizumab in combination with eftilagimod alpha and radiotherapy in neoadjuvant treatment of patients with soft tissue sarcomas: EFTISARC-NEO trial
Authors: K. Kozak, P. Sobczuk, S. Kopeć, T. Switaj, P. Teterycz, A. Borkowska, P. Rutkowski
Journal: Annals of Oncology (2023)
2395P Micropapillary histology (MPUC) and extra-cellular domain ERBB2 (ERBB2 ECD+) mutations in urothelial bladder cancer (UBC)
Authors: A. Sood, J.M. Jacob, G. Bratslavsky, P. Grivas, P. Spiess, R. Li, A. Necchi, J. Posada, E. Yakirevich, L. Cheng, D.C. Pavlick, R. Huang, D.I. Lin, N.A. Danziger, E.S. Sokol, S. Sivakumar, J.S. Ross, A. Kamat
Journal: Annals of Oncology (2023)
1973P Antitumor activity of olverembatinib (HQP1351) in patients (pts) with TKI-resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST)
Authors: H. Qiu, Z. Zhou, Y. Zhou, X. Wan, N. Li, K. Tao, Y. Li, X. Wu, Z. Chen, L. Liu, L. Men, H. Wang, E. Liang, P. Min, C. Wang, L. Jiang, D. Yang, Y. Zhai, R-H. Xu
Journal: Annals of Oncology (2023)
1918MO Circulating tumor DNA in relation to tumor volume in gastro-intestinal stromal tumors
Authors: R.F. Bleckman, C. Haag, R.H. Mathijssen, N. Steeghs, H. Gelderblom, I.M. Desar, A. Ter Elst, E. Schuuring, A.K.L. Reyners
Journal: Annals of Oncology (2023)
1933P Perioperative chemotherapy could reduce the risk of recurrence in resected leiomyosarcoma of the vena cava (LMS-VC): A retrospective bi-centric series on 41 patients
Authors: T. Bertrand, M. Faron, O. Mercier, C. Ngo, C. Le Pechoux, A. Levy, J. Issard, C. Henon, C. Honoré, E. Fadel, A. Le Cesne
Journal: Annals of Oncology (2023)
1924P Targeting microenvironment and cellular immunity in sarcomas with trabectedin combined with metronomic cyclophosphamide: The TARMIC study
Authors: C-M. Sun, I. Hernandez, M. Spalato Ceruso, M. Toulmonde, C. Sautes-Fridman, W-H. Fridman, A. Bessede, A. Italiano
Journal: Annals of Oncology (2023)
1950P A single-arm, phase II clinical trial of neoadjuvant pegylated liposomal doxorubicin plus anlotinib in locally advanced soft tissue sarcoma
Authors: Y. Chen, W. Sun, S. Wang, Y. Xu, T. Hu, B. Zheng, Z. Sun, C. Wang, W. Yan
Journal: Annals of Oncology (2023)
2387P Avelumab first-line maintenance (1LM) for locally advanced or metastatic urothelial carcinoma (la/mUC): Treatment (tx) patterns and real-world (rw) outcomes in the US
Authors: K. Carson, H. Mahmoudpour, C. Ike, S. Monzon, S. Fragkogianni, J. Ferrer, M. Kearney
Journal: Annals of Oncology (2023)
1979P phase I trial of pembrolizumab in HIV-associated Kaposi sarcoma (KS)
Authors: K. Lurain, R. Ramaswami, I. Ekwede, V. Eulo, G. Goyal, M. Menon, T.A. Odeny, E. Sharon, M. Wagner, C-C. Wang, N. Bhardwaj, M. Abdul-Hay, J. Kaiser, A. Wright, R. Yarchoan, S.P. Fling, Q. Lu, T.S. Uldrick
Journal: Annals of Oncology (2023)
1921MO Patterns of care, outcome and molecular landscape of PATZ1-rearranged sarcomas identifies two prognostic profiles: A cohort study from the French Sarcoma Group (FSG)
Authors: H. Vanacker, F. Le Loarer, M. Karanian, A. Meurgey, A. Dufresne, S. El Zein, J-Y. Blay, O. Collard, I.L. Ray-Coquard, W.A. Waissi, D. Pissaloux, S. Paindavoine, A. Houlier, G. Pierron, P. Meeus, F. Tirode, M. Brahmi
Journal: Annals of Oncology (2023)

PATZ1 rearranged sarcomas (PRS) belong to the "round cell sarcomas with EWSR1–non-ETS fusions" group in 2020's WHO classifications. With only small case series (<10 cases) reporting deep clinical and histological heterogeneity, uncertain prognosis and absence of standard of care, PRS imperatively require further clinico-molecular characterization. Pediatric and adult patients from 13 French centers with a diagnosis of PRS from 2011 to March 2023 were included. All PRS diagnosis were histologically and molecularly reviewed by 4 expert pathologists. Patients and tumors characteristics were collected from the national NETSARC+ database (netsarc.sarcomabcb.org) and whole exome-RNAseq was performed with FFPE material. Seventeen patients were included with a mean follow up of 44 months including 16 with EWSR1::PATZ1 and one with MN1::PATZ1 fusions. Clinical data were heterogeneous in term of baseline clinical characteristics, histopathology, management and outcome. In univariate analyses, age, tumor size, FNCLCC-grade, adjuvant systemic therapy for non-metastatic disease did not correlate to overall survival (OS) whereas stage, Ki67 and some transcriptomic signatures -relative to cell cycle- did. A group of patients with metastasis or Ki67>30% had aggressive clinical course and poor responses to treatment (whether Ewing-like regimen or other). A distinct group of patients had indolent profiles and were long-term free of recurrence (>5years) after surgery alone without adjuvant chemo/radiotherapy. Table: 1921MOUnivariate analysis of OS using the Cox model: Median OS is 33.5 months (range 5 :120)ParameterVariableN=HRCI95%P-ValueP level1AgeContinuous171.01(0.98;1.05)0.378nsSexM vs F11 vs 62.02(0.279;7.24)0.279nsTumor size (mm)Continuous171.02(0.99;1.04)0.053nsPrimary siteTrunk vs others7 vs 101.4(0.43;4.70)0.55nsStage (initial)Localized/loc.Adv. vs Metastatic10 vs 721.1(2.942;2.94)2.942**Ki67% (adult)Continuous91.02(1.02;)0.0274*Grade (FNCLCC)Grade 2 vs 38 vs 70.59(0.16;2.15)0.427nsRNAseq cell cycle G2_M scoreContinuous154.1243(1.33;12.76)0.0139*Adjuvant systemic treatmentSystemic treatment vs Surveillance7 vs 3 all no metastasis0.46(0.04;4.9)0.52ns1 level of significance: p>0.05:ns; p<0.05:*,p<0.01:**;p<0.001:** Open table in a new tab 1 level of significance: p>0.05:ns; p<0.05:*,p<0.01:**;p<0.001:** Our study suggests that the natural history pf PRS differs from Ewing sarcomas. We reveal that some good prognosis PRS are cured with surgery alone while others are aggressive. Stage and ki67 should help to identify those patients while further molecular analyzes are pending.
1927P Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years
Authors: A. Le Cesne, J-Y. Blay, S. Piperno-Neumann, S. Watson, A. Dufresne, T. Valentin, F. Duffaud, M. Toulmonde, A. Italiano, F. Bertucci, C. Tlemsani, N. Firmin, E. Bompas, C. Perrin, E.B. Saada, P. Dubray-Longeras, A. Hervieu, F. Ducimetiere, M. Brahmi, N. Penel
Journal: Annals of Oncology (2023)
1955P Distinguishing lipomas from atypical lipomatous tumors/well differentiated liposarcomas in histology slides using deep learning
Authors: M. Karanian, A. Camara, J. Klein, T. Marchand, C. Maussion, V. Rousseau, T. Bonnotte, R. Perret, F. Le Loarer, C. Ngo, S. Korbi, Y. Mansour, A. Meurgey, M. Jean-Denis, A. Italiano, J-Y. Blay, J.M. Coindre
Journal: Annals of Oncology (2023)
1943P Efficacy and safety of eribulin plus anlotinib and camrelizumab in advanced or metastatic retroperitoneal liposarcoma (RLPS) or leiomyosarcoma (RLMS): A single-center retrospective cohort study
Authors: J. Wu, C. Hao, W. Jia, A. Lv, H. Qiu, C. Li, B. Liu, Q. Liu, D. Liu, Z. Wang, R. Sun, X. Wang, G. Xue, X. Tian
Journal: Annals of Oncology (2023)